Severe hepatotoxicity in a patient on bosentan upon addition of methotrexate: reversible with resumption of methotrexate without bosentan.
Dwyer
Nathan
N
Department of Cardiology, Royal Hobart Hospital, Tasmania, Australia. ndwyer@utas.edu.au
Jones
Graeme
G
Kilpatrick
David
D
D000959:Antihypertensive Agents / Q000009:adverse effects*; D000077300:Bosentan; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D003879:Dermatologic Agents / Q000009:adverse effects*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications / Q000188:drug therapy; D008727:Methotrexate / Q000009:adverse effects*; D008875:Middle Aged; D019338:Polypharmacy; D012595:Scleroderma, Systemic / Q000150:complications / Q000188:drug therapy*; D013449:Sulfonamides / Q000009:adverse effects*
D000959:Antihypertensive Agents; D003879:Dermatologic Agents; D013449:Sulfonamides; D000077300:Bosentan; D008727:Methotrexate